MedScout Collects $10 Million in New Funding

MedScout has raised $10 million in a growth round led by Fulcrum Equity Partners, with participation from existing investors Live Oak Ventures and Stage 2 Capital. The round more than doubled the company’s valuation from its Series A and will be used to fund continued investment in its artificial intelligence (AI) capabilities as well as support growing demand from enterprise customers.

“MedScout is tackling one of the most pressing challenges in medtech: turning company strategy into revenue performance,” said Philip Lewis, a partner at Fulcrum Equity Partners. “What they’ve built combines commercial expertise and AI to solve that problem in a highly actionable way that’s unique to each customer. This is the future of how companies put AI to work, and it’s why we’re doubling down on our investment in MedScout.”

Alongside the funding, MedScout is launching Strategies—AI agents that analyze market and account-level referral networks, procedure volumes, payer dynamics, and more to deliver prioritized, ready-to-work territory plans to reps.

“Medtech companies spend months developing commercial strategies that don’t make it to the field as intended,” MedScout Co-Founder/CEO Skylar Talley stated. “MedScout bridges that gap by translating commercial priorities into clear, territory-specific actions. Sales reps know which providers to prioritize and how to build and expand those relationships.”

Medtech commercial teams face a core disconnect: strategy is set at the top, but the tools reps use in the field don’t reflect it. Instead, reps rely on Google, stale spreadsheets, or data platforms that lack the context to tell them the factors that matter most.

Each Strategy is an AI agent built around a company’s specific commercial context, the ways it wins in the market, and its definition of a best-fit target. Drawing on industry expertise and field-tested patterns from working with hundreds of medtech commercial teams, each agent can pinpoint the accounts and physicians most likely to convert. MedScout made Strategies available to customers late last year.

“In January, our customers deployed 81% more unique AI agents than the month before, evidence that sales teams are seeing value quickly and building on early success,” Talley noted.

MedScout’s growth reflects the urgency of the problem it solves, according to the company. Enterprise medical technology organizations are increasingly relying on MedScout to keep their large and distributed sales forces focused on the right accounts and opportunities. Enterprise revenue has grown threefold since its Series A found in July 2024, and monthly active reps are up 135% month over month as sales teams expand their use of Strategies.

“Everything we do is in service of better patient outcomes, and that starts with getting our innovations into the hands of the right clinicians,” said Meraj Khan, chief marketing officer, Surgical Innovations at GE HealthCare. “MedScout has been a strategic partner in helping our field teams identify, prioritize, and connect with the facilities and providers where our technologies can have the greatest impact. The result is stronger commercial performance and more patients benefiting from precision care. We’re proud to work with MedScout and excited for this next phase of our partnership.”

MedScout customers deploy Strategies aligned to their specific growth priorities and market positioning, such as:

• A surgical robotics company pinpoints orthopedic surgeons who perform high volumes of traditional total knee replacements, have a Medicare-heavy patient mix (60%-plus), and haven’t adopted robotic-assisted procedures. Reps get a clear list of high-fit targets where the clinical case for adoption is already established.
• A diagnostic imaging company identifies primary care physicians within a 25-mile radius of a priority account who see patients with pulmonary nodules but refer lung biopsies to competing practices. Reps receive a prioritized list of physicians whose referral patterns offer the greatest opportunity to expand biopsy volume at the target facility.
• A cardiology device company identifies hospitals that performed 30% fewer TAVR procedures year over year while maintaining more than 250 annual cardiac catheterization cases. Reps get a ranked list of high-capacity programs losing structural heart volume—a clear signal to re-evaluate technology partnerships. Each site has a tailored ROI story that quantifies revenue at risk and frames a path to recapture volume.

‍MedScout is a commercial engine for medical device and diagnostics companies. AI agents translate commercial strategy into execution, delivering territory plans to sales reps by analyzing procedure volumes, referral networks, payer dynamics, and real-world adoption signals. MedScout integrates directly into the CRMs and commercial workflows sales teams already rely on, amplifying the power of existing tools.

Fulcrum Equity Partners is an Atlanta-based growth equity firm investing in B2B software and healthcare services companies. With more than 125 years of combined operating experience across its partners, over 60 investments, and approaching $1 billion in assets under management, Fulcrum partners with companies to build enduring businesses.